See more than ever before

The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.

Lymphoma assay extensively validated in hundreds of patients with B-cell malignancies

Detect relapse 200+ days earlier By detecting 1 part per million

See what others miss

Latest Updates

Dec 19, 2022

Data supporting the routine use of PhasED-Seq® for MRD analysis in DLBCL featured in Precision Oncology News

Nov 29, 2022

Foresight Diagnostics Announces Three Presentations Highlighting Clinical Studies from their Patented PhasED-Seq®MRD Platform at the 64th American Society of Hematology Annual Meeting and Exposition

Sep 27, 2022

Foresight Diagnostics Patent Issued for Minimal Residual Disease Detection Technology  